Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Alberta

About this trial

CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to collect, store, and analyze vast amounts of multimodal information about ALS. These multimodal datasets and biosamples will be made available for use by researchers or industry across Canada and around the world in accordance with the CAPTURE ALS Data Sharing Policy to advance research on ALS.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Has ALS, classified as definite, probable, laboratory-supported probable, or possible ALS according to the revised El Escorial criteria or a related neurodegenerative disorder including ALS-FTD, PLS, PMA or asymptomatic individuals with a known ALS mutation (as previously confirmed during regular clinical care)

Be of the age of majority in their province of residence/treatment

Have the cognitive capacity to provide informed consent

Have proficiency in English or French in order to understand study instructions and respond to questionnaires

Disqualifiers

Be between the ages of 40-80 unless age matched to a patient (+/-3 years) who is already enrolled

Be the age of majority in their province of residence/treatment

Have the cognitive capacity to provide informed consent

Have proficiency in English of French to understand study instructions and respond to questionnaires

Trial population

People living with ALS and related motor neuron diseases including ALS-Frontotemporal Dementia (ALS-FTD), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA) and asymptomatic individuals with a known ALS mutation AND Healthy controls that are age and sex matched to patients

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

ALS Functional Rating Scale-Revised (ALSFRS-R)

The ALSFRS-R will be used as a global measure of disease status. It measures activities of daily living and consists of 12 questions, each scored from 0-4, with higher scores representing better function. Changes in ALSFRS-R score over time will be measured.

Time frame
Once every 4 months for a year
2

Forced Vital Capacity (FVC)

FVC will be used as an index of respiratory function over time. FVC is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration.

Time frame
Once every 4 months for a year
3

Speech Testing

Changes in speech function over time will be measured using a web-browser based audio and video data collection tool.

Time frame
Once every 4 months for a year
4

Neurological dysfunction as detected during standard neurological examination

Changes in neurological function over time will be measured through a standard neurological examination.

Time frame
Once every 4 months for a year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Alberta

Lead sponsor

McGill University

Collaborator

Laval University

Collaborator

University of Toronto

Collaborator

Simon Fraser University

Collaborator